



Title	Astilbe thunbergii reduces postprandial hyperglycemia in a type 2 diabetes rat model via pancreatic alpha-amylase inhibition by highly condensed procyanidins
Author(s)	Kato, Eisuke; Kushibiki, Natsuka; Inagaki, Yosuke; Kurokawa, Mihoko; Kawabata, Jun
Citation	Bioscience biotechnology and biochemistry, 81(9), 1699-1705 https://doi.org/10.1080/09168451.2017.1353403
Issue Date	2017-09
Doc URL	http://hdl.handle.net/2115/71428
Rights	This is an Accepted Manuscript of an article published by Taylor & Francis in Bioscience biotechnology & biochemistry on 2017 Sep, available online: http://www.tandfonline.com/10.1080/09168451.2017.1353403 .
Type	article (author version)
File Information	BBB2017_81_1699-1705_postprint.pdf



[Instructions for use](#)

1 Author's post-print manuscript of the following article
2 *
3 *Astilbe thunbergii* reduces postprandial hyperglycemia in a type 2 diabetes rat
4 model via pancreatic alpha-amylase inhibition by highly condensed
5 procyanidins.

6
7 Bioscience, Biotechnology, and Biochemistry, 2017, 81(9), 1699-1705.
8 Check the published version from the bellow link.

9
10 Taylers & Francis Online

11 DOI:10.1080/09168451.2017.1353403

12 <http://www.tandfonline.com/doi/full/10.1080/09168451.2017.1353403>

13

14

15 E. Kato *et al.*

16 Anti-diabetic effect of *Astilbe thunbergii*

17

18 **Research Article**

19 ***Astilbe thunbergii* reduces postprandial hyperglycemia in a type 2 diabetes**

20 **rat model via pancreatic alpha-amylase inhibition by highly condensed**

21 **procyanidins.**

22 Eisuke Kato^{1*}, Natsuka Kushibiki¹, Yosuke Inagaki², Mihoko Kurokawa², Jun

23 Kawabata¹

24 ¹Laboratory of Food Biochemistry, Division of Applied Bioscience, Graduate School
25 of Agriculture, Hokkaido University, Kita-ku, Sapporo, Hokkaido 060-8589, Japan

26 ²Q'sai Co., Ltd., Kusagae, Fukuoka, Fukuoka 810-8606, Japan

27

28 *Corresponding author

29 Tel/Fax: +81 11 706 2496;

30 E-mail address: eikato@chem.agr.hokudai.ac.jp (E. Kato)

31

32 **Abstract**

33 Type 2 diabetes mellitus (T2DM) is a common global health problem. Prevention
34 of this disease is an important task, and functional food supplements are
35 considered an effective method. We found potent pancreatic α -amylase
36 inhibition in *Astilbe thunbergii* root extract (AT) and confirmed that AT treatment
37 in a T2DM rat model reduces post-starch administration blood glucose levels.
38 Activity-guided isolation revealed procyanidin (AT-P) as the α -amylase inhibitory
39 component with $IC_{50} = 1.7 \mu\text{g/mL}$ against porcine pancreatic α -amylase.
40 Structure analysis of AT-P revealed it is a B-type procyanidin comprised of four
41 types of flavan-3-ols, some with a galloyl group, and catechin attached as the
42 terminal unit. The abundant AT-P content and its comparable α -amylase
43 inhibition to acarbose, the anti-diabetic medicine, suggests that AT is a
44 promising food supplement for diabetes prevention.

45

46 **Keywords:** pancreatic α -amylase; type 2 diabetes; procyanidin; *Astilbe thunbergii*

47

48 Type 2 diabetes mellitus (T2DM) is a significant global problem, with patient
49 numbers increasing every year. Although numerous anti-diabetes medications
50 have been developed and utilized, they are not effective at completely curing the
51 disease [1,2]. Therefore, a method for prevention is as important as a method for
52 treatment of the disease.

53 Functional food supplements are an effective way of preventing
54 lifestyle-dependent diseases, including diabetes. Components in food display
55 various functions in the digestive tract that have benefits for maintaining health.
56 The inhibition of carbohydrate digestive enzymes is one of these functions with
57 anti-diabetic properties [3].

58 *A. thunbergii* is a perennial plant that belongs to the Saxifragaceae family and is
59 distributed widely along mountainous regions in Japan. The plant has been used
60 as an alternative to the *Cimicifuga* genus (*C. dahurica*, *C. foetida*, and *C.*
61 *heracleifolia*), which is employed in traditional Japanese and Chinese medicine.
62 "Sheng Ma," derived from the *Cimicifuga* genus, has been used as a diaphoretic
63 and antipyretic agent and for prevention of gastroptosis and proctoptosis [4,5].
64 As an alternative plant, *A. thunbergii* has also been used for these purposes. In
65 addition, scientific studies investigating this plant have identified an anti-obesity
66 effect, such as enhancement of lipolysis, inhibition of pancreatic lipase, and
67 reduction of plasma triacylglycerol levels in high-fat diet-treated rats [6,7].

68 Obesity is one of the health problems associated with T2DM. Studying the
69 anti-diabetic properties of *A. thunbergii* will concomitantly clarify the
70 anti-obesity effects and will allow the enhanced utilization of this plant for both

71 anti-obesity and anti-diabetic purposes.

72 Here, we evaluated the anti-diabetic property of *A. thunbergii* root extract (AT)
73 through *in vitro* α -amylase inhibitory activity assay, and confirmed its effect in a
74 T2DM rat model. Activity-guided isolation revealed procyanidin in AT (AT-P),
75 which is constituted from four types of flavan-3-ols, as the major α -amylase
76 inhibitory component

77

78 **Materials and methods**

79 *General*

80 Chemicals were purchased from Wako Pure Chemical Industries, Ltd. (Osaka,
81 Japan) unless otherwise noted. Absorbance was measured using a Synergy™ MX
82 microplate reader (BioTek Instruments, Inc.). Bruker AMX 500 (Bruker BioSpin
83 K.K.) was used to obtain nuclear magnetic resonance (NMR) spectra, and residual
84 solvents were used as an internal standard (acetone-*d*₆: ¹H 2.04 ppm). Waters LCT
85 Premier Spectrometer (Waters Co.) was used to obtain mass spectra and was
86 combined with the Waters Acquity UPLC system (Waters Co.) for liquid
87 chromatography-mass spectrometry (LC-MS) analysis.

88

89 *A. thunbergii extract (AT) powder*

90 AT was a commercial product of BHN Co, Ltd. (Lot No. 100915, Tokyo, Japan).
91 According to the distributor, the extract powder was processed from the root of
92 *A. thunbergii* using 50-60% aq. ethanol as the extracting solvent.

93

94 *Animal study*

95 Five-week-old male GK:Slc rats supplied from Japan SLC, Inc. (Hamamatsu, Japan)
96 were acclimated at 20–26°C, 12 h light/dark cycle for 1 week with free access to
97 water and a standard rodent diet. All experiments were performed following
98 Hokudo Co., Ltd (Sapporo, Japan) animal experiment regulations.

99

100 *Sugar tolerance test*

101 Rats were fasted for 18 h and then orally administered each dose of the sample
102 suspended in distilled water, followed by administration of starch, sucrose, or
103 glucose (2 g/kg). Blood samples were obtained from the tail vein, and blood
104 glucose levels were measured by Nipro FreeStyle Freedom Lite (Nipro Co., Osaka,
105 Japan).

106

107 *Insulin and glucagon-like peptide-1 (GLP-1) levels*

108 Insulin and GLP-1 levels were measured during the first 30 min of the glucose
109 tolerance test. Rats were anesthetized by isoflurane (DS Pharma Animal Health
110 Co., Ltd., Osaka, Japan), and blood samples were obtained from the jugular vein.
111 For the GLP-1 measurement, diprotin A (Peptide Institute, Inc., Osaka, Japan) and
112 protease inhibitor cocktail (Sigma-Aldrich Co., P2714) were added to the blood
113 samples immediately after collection. Insulin levels were measured using a rat
114 insulin ELISA kit (MS301, Morinaga Institute of Biological Science, Inc., Yokohama,
115 Japan). GLP-1 levels were measured using a GLP-1, Active form Assay Kit – IBL
116 (Immuno-Biological Laboratories Co., Ltd., Fujioka, Japan).

117

118 *Isolation of procyanidin from AT*

119 AT (22.74 g) was suspended in water (1 L) and stirred for 1 hour. The resulting
120 solution was filtered, and the filtrate was applied to a DIAION HP-20 (Mitsubishi
121 Chemical Co.) column. The column was washed with water and eluted with 50%
122 aq. methanol. The 50% aq. methanol eluate was then directly applied to a
123 Sephadex LH-20 (GE Healthcare Japan Co.) column. The column was washed
124 sequentially with 50% aq. methanol and methanol and then eluted with 70% aq.
125 acetone to obtain *A. thunbergii* procyanidin (AT-P, 2.52 g).

126

127 *Vanillin assay* [8]

128 The AT-P methanol solution (0.5 mL), 35% hydrochloric acid (1.5 mL), and 4%
129 (w/v) vanillin in methanol (3.0 mL) were mixed and incubated for 15 min at room
130 temperature. The reaction mixture was measured for its A₅₀₀ and compared with
131 the standard curve of (+)-catechin.

132

133 *Analysis of AT-P by gel permeation chromatography (GPC)*

134 AT-P was dissolved in N,N-dimethylformamide containing 10 mM lithium
135 bromide and analyzed by HPLC equipped with Shodex GF-510 HQ (φ7.5×300
136 mm, Showa Denko K.K., Tokyo). The mobile phase was 10 mM lithium bromide in
137 N,N-dimethylformamide with a flow rate of 0.4 mL/min at room temperature.
138 Polystyrene (Agilent EasiVial Polystyrene High MW, Agilent Technologies Japan,
139 Ltd.) was used for the standards.

140

141 *Thiolysis of AT-P*

142 AT-P (523.4 mg) was dissolved in 0.1 M hydrogen chloride in methanol (40 mL),

143 and benzyl mercaptan (1 mL) was added. The mixture was stirred for 90 min at
144 40°C under nitrogen atmosphere. Part of the reaction mixture was dried and
145 analyzed by HPLC (Figure 4). The ratio of each compound was estimated from
146 the peak area after adjustment using commercial catechin, epicatechin,
147 epigallocatechin, epicatechin gallate, and epigallocatechin gallate as the
148 standards.

149 The rest of the reaction mixture was evaporated to remove the methanol, diluted
150 with water, and extracted by ethyl acetate. The organic layer was washed with
151 brine, dried over sodium sulfate, and evaporated. The residue was purified by
152 HPLC using an InertSustain C18 column (GL Science Inc., Tokyo, Japan) with
153 gradient elution (from 40% aq. methanol with 0.1% trifluoroacetic acid [TFA] to
154 95% aq. methanol with 0.1% TFA for 30 min, flow rate 1.0 mL/min, detection UV
155 280 nm) to obtain four benzyl mercaptan adducts (**2–4**, and **6**). The obtained
156 products were analyzed by ^1H -NMR to determine their structures.

157 Compound **2** (gallocatechin 4-benzylthioether)[9,10]

158 HR-ESI-MS (positive): $[\text{M}+\text{H}]^+$ calcd. for $\text{C}_{22}\text{H}_{21}\text{O}_7\text{S}$, *m/z* 429.1008, found
159 429.1011; ^1H -NMR (500 MHz, acetone-*d*₆): 4.07 (1H, d, *J* = 12.5 Hz), 4.13 (1H, d, *J*
160 = 12.5 Hz), 4.08–4.13 (1H, m), 4.37 (1H, d, *J* = 4.1 Hz), 4.88 (1H, d, *J* = 9.8 Hz), 5.81
161 (1H, d, *J* = 2.2 Hz), 6.01 (1H, d, *J* = 2.2 Hz), 6.51 (2H, s), 7.19–7.42 (5H, m) ppm.

162 Compound **3** (epigallocatechin 4-benzylthioether)[10]

163 HR-ESI-MS (positive): $[\text{M}+\text{H}]^+$ calcd. for $\text{C}_{22}\text{H}_{21}\text{O}_7\text{S}$, *m/z* 429.1008; found,
164 429.1023; ^1H -NMR (500 MHz, acetone-*d*₆): 3.99 (1H, br s), 4.00 (1H, d, *J* = 12.6 Hz),
165 4.04 (1H, d, *J* = 12.6 Hz), 4.06 (1H, d, *J* = 2.2 Hz), 5.20 (1H, s), 5.89 (1H, d, *J* = 2.2
166 Hz), 6.01 (1H, d, *J* = 2.2 Hz), 6.55 (2H, s), 7.22 (1H, t, *J* = 7.5 Hz), 7.31 (2H, dd, *J* =

167 7.5, 7.5 Hz), 7.45 (2H, d, *J* = 7.5 Hz) ppm.

168 Compound **4** (catechin 4-benzylthioether)[10]

169 HR-ESI-MS (positive): [M+H]⁺ calcd. for C₂₂H₂₁O₆S, *m/z* 413.1059; found,
170 413.1077; ¹H-NMR (500 MHz, acetone-*d*₆): 4.07 (1H, d, *J* = 12.3 Hz), 4.12 (1H, d, *J*
171 = 12.3 Hz), 4.14 (1H, dd, *J* = 4.2, 9.8 Hz), 4.38 (1H, d, *J* = 4.2 Hz), 4.94 (1H, d, *J* =
172 9.8 Hz), 5.81 (1H, d, *J* = 2.2 Hz), 6.02 (1H, d, *J* = 2.2 Hz), 6.81 (2H, m), 6.94 (1H, br
173 s), 7.20 (1H, t, *J* = 7.3 Hz), 7.28 (2H, dd, *J* = 7.3, 7.6 Hz), 7.41 (2H, d, *J* = 7.6 Hz)
174 ppm.

175 Compound **6** (epicatechin 4-benzylthioether)[10]

176 HR-ESI-MS (positive): [M+H]⁺ calcd. for C₂₂H₂₁O₆S, *m/z* 429.1059; found,
177 429.1043; ¹H-NMR (500 MHz, acetone-*d*₆): 3.98 (1H, s), 4.00 (1H, d, *J* = 13.2 Hz),
178 4.04 (1H, d, *J* = 13.2 Hz), 4.08 (1H, d, *J* = 1.9 Hz), 5.26 (1H, s), 5.89 (1H, d, *J* = 2.2
179 Hz), 6.02 (1H, d, *J* = 2.2 Hz), 6.76 (1H, dd, *J* = 1.6, 8.2 Hz), 6.79 (1H, d, *J* = 8.2 Hz),
180 7.03 (1H, d, *J* = 1.6 Hz), 7.22 (1H, t, *J* = 7.3 Hz), 7.31 (2H, dd, *J* = 7.3, 7.3 Hz), 7.45
181 (2H, d, *J* = 7.3 Hz) ppm.

182

183 *Pancreatic α-amylase inhibitory activity*

184 The α-amylase inhibitory activity was determined using the method described by
185 Hansawasdi et al [11]. Briefly, 350 μL of starch azure (4 mg/mL, Sigma-Aldrich Co.,
186 S7629) suspended in Tris-HCl buffer (0.1 M, pH6.9, 0.01 M CaCl₂), 100 μL of
187 sample dissolved in water, and 50 μL of porcine pancreatic α-amylase dissolved
188 in Tris-HCl buffer were incubated for 10 min at 37°C with frequent mixing. The
189 reaction was stopped by the addition of 50% acetic acid (50 μL) and then
190 centrifuged (1,500 × *g*, 5 min), and the A₅₉₅ of the supernatant was measured.

191 The IC₅₀ value was calculated using curve fitting by NIH Image J software.

192

193 **Statistics**

194 *In vivo* experiments were performed with n=7 rats/group, and Bartlett's test was
195 used to analyze the homogeneity of variance. Homoscedastic data were analyzed
196 by one-way ANOVA, and heteroscedastic data were analyzed by Kruskal-Wallis
197 test. Data with significant differences were subsequently analyzed by Dunnett
198 multiple comparison test to determine the significance compared with the
199 control. *p*<0.05 was considered significant. *In vitro* experiments were performed
200 in duplicate and repeated at least two times. Average values are shown in the
201 figures. Statistical significance was determined using one-way ANOVA coupled
202 with Dunnett multiple comparison test, and *p*<0.01 was considered significant.

203

204 **Results and discussion**

205 *In vitro* α -amylase inhibitory activity assay of AT displayed a 90% inhibition at 0.1
206 mg/mL indicating its potential anti-diabetic effect. The anti-diabetic effect of AT
207 was confirmed by *in vivo* experiments. Male GK:Slc rats, a T2DM model [12], were
208 orally administered AT. Rats then underwent a sugar tolerance test for either
209 starch, glucose, or sucrose, and blood glucose levels were analyzed (Figure 1). In
210 addition, serum GLP-1 and insulin levels were measured (Figures 2).

211

Figure 1

212

Figure 2

213 When starch was loaded following AT administration (100 or 300 mg/kg), the
214 elevation in blood glucose levels in rats was reduced by approximately 30% at 30
215 min ($p<0.05$) and 40% at 60 min ($p<0.01$) compared with those of the control
216 (Figure 1A). The area under the curve (AUC) was also decreased by 21% in the
217 100 mg/kg group and 24% in the 300 mg/kg group ($p<0.01$). These results
218 revealed the efficacy of AT at mitigating the rapid elevation in blood glucose
219 levels following food consumption.

220 During the sucrose tolerance test, 300 mg/kg AT-administered rats displayed an
221 approximately 25% reduction in blood glucose levels at 90 and 120 min ($p<0.05$),
222 and the AUC decreased by 17% ($p<0.01$) (Figure 1B,C). The glucose tolerance test
223 did not reveal differences between the doses. Serum GLP-1 levels were 1.2–1.6
224 times higher in the AT-administered group than those of the control group at 30
225 min post administration ($p<0.01$), but insulin levels did not significantly differ at
226 this time point (Figure 2).

227 The above results indicate that AT efficiently reduced the rapid elevation in
228 post-meal blood glucose levels. The underlying mechanism is primarily through
229 the inhibition of starch digestion by α -amylase but not through the inhibition of
230 glucose absorption or increased insulin secretion. Inhibition of α -glucosidase
231 and dipeptidyl peptidase IV or enhanced secretion of GLP-1 from L-cells may
232 accompany this mechanism but with relatively minor contributions.

233 Following the *in vivo* results, the active component in AT that inhibits α -amylase
234 was determined through an activity-guided isolation procedure. Solvent

partition of AT between water, 1-butanol, and ethyl acetate gave water layer as the active layer. The water layer was separated by column chromatography employing Diaion HP-20 (Mitsubishi Chemical Co.), Cosmosil 75C₁₈-OPN (Nakalai Tesque, Inc.), and Toyopearl HW-40F (Tosoh Co.) to give an active fraction consisting primarily of procyanidin with presumably large size which was predicted through the elution character in each column and spectroscopic methods.

The procedure was thus optimized to achieve an effective separation of procyanidins from AT. The water-soluble portion of AT was absorbed on a DIAION HP-20 column, washed, and eluted with 50% methanol. This was then absorbed on a Sephadex LH-20 column, washed, and eluted with 70% acetone to obtain AT procyanidin (AT-P, yield 11.1% w/w from AT) which has identical character (reverse phase HPLC, GPC and thiolysis product analysis) with the procyanidin isolated through the activity guided fractionation.

249

Figure 3

Characterization of the isolated AT-P was performed through several methods. A vanillin assay, a colorimetric method to determine procyanidin content, revealed that 1 mg of AT-P is equivalent to 0.79 ± 0.02 mg of (+)-catechin. A UV spectra of AT-P revealed a peak at 280 nm, which is similar to that of (+)-catechin, indicating that the majority of AT-P consists of flavan-3-ols (Figure 3A).

The degree of polymerization of AT-P was analyzed by HPLC analysis employing

256 a diol column, with the condition suitable to analyze procyanidin with a
257 polymerization degree below n<10. No peak was detected, indicating a high
258 level of polymerization [13,14]. Consistent with this, MALDI and ESI-MS analysis
259 of AT-P did not reveal any distinguishable ions resulting from procyanidin.

260 To obtain information regarding molecular size, gel permeation chromatography
261 was performed with a Shodex GF-510 HQ column [15]. The chromatogram of
262 AT-P revealed a single peak with an elution volume at the relatively large
263 molecular size region (Figure 3B). The molecular size of the peak was
264 approximately 8,260, estimated from the standard curve of polystyrene. This
265 estimation is probably not accurate because of differences in the structure
266 between standards and AT-P. However, this result suggests that AT-P is a highly
267 condensed procyanidin and does not contain lower size molecules.

268 Figure 4

269 Next, thiolysis of AT-P was performed to determine the units and estimate the
270 degree of polymerization. AT-P was heated under acidic conditions in the
271 presence of benzyl mercaptan. Analysis of the reaction mixture revealed seven
272 main products (Figure 4). Product **1** was determined to be catechin by
273 comparison with the standard, which is the terminal unit of AT-P. Products **2-4**
274 and **6** were isolated and analyzed by ¹H-NMR and MS and determined to be
275 gallicatechin 4-benzylthioether (**2**), epigallicatechin 4-benzylthioether (**3**),
276 catechin 4-benzylthioether (**4**), and epicatechin 4-benzylthioether (**6**) (Figure
277 5)[9,10]. Because of the failure to isolate products **5** and **7**, the reaction mixture

278 was analyzed by LC-MS, and the two remaining products were determined to be
279 (epi)gallocatechin gallate 4-benzylthioether (**5**) and (epi)catechin gallate
280 4-benzylthioether (**7**) (Figure 5). From the results of LC-MS, we would like to note
281 that A-type procyanidin-derived products, which are frequently contained in the
282 structure of procyanidins, were not detected. These results gave information
283 regarding the structure of AT-P, which is a B-type procyanidin comprised of four
284 types of flavan-3-ols, some with a galloyl group and catechin attached as the
285 terminal unit. The ratio of the terminal unit and benzyl mercaptan adducts (**2–7**)
286 was estimated from the HPLC chromatogram (Table 1). From the estimated ratio,
287 the mean degree of polymerization (mDP) was calculated to be 11.8 ± 0.1 . The
288 presence of the four types of flavan-3-ol units (catechin, gallocatechin,
289 epicatechin, and epigallocatechin) is characteristic of AT-P, since previously
290 reported procyanidins are frequently constructed from 1–3 types of flavan-3-ols
291 [16–21].

292 Figure 5

293 Table 1

294 Figure 6

295 AT-P was analyzed for its α -amylase inhibitory activity (Figure 6). AT-P showed
296 concentration-dependent inhibition of α -amylase with IC_{50} 1.7 $\mu\text{g/mL}$. When
297 compared at the same concentration, AT-P showed relatively higher activity (85%
298 at 5 $\mu\text{g/mL}$) than acarbose (61% at 5 $\mu\text{g/mL}$), the positive control used in the

299 experiment and a medicinally-employed α -amylase inhibitor. The potent activity
300 of AT-P and its high yield from AT clearly indicate that it is the major contributor
301 of α -amylase inhibitory activity in AT.

302 Various procyanidins contained in plants are reported to inhibit α -amylase.
303 Procyanidins from cinnamon ($IC_{50} = 4.8 \mu\text{g/mL}$) [22], almond ($IC_{50} = 2.2 \mu\text{g/mL}$)
304 [23], sapodilla ($IC_{50} = 4.2 \mu\text{g/mL}$) [16], and *Polygonum multiflorum* ($IC_{50} = 2.9$
305 $\mu\text{g/mL}$) [17] display comparable α -amylase inhibitory activity to the currently
306 isolated AT-P. In contrast, persimmon peel and leaf (54% at 100 $\mu\text{g/mL}$ and 64%
307 at 240 $\mu\text{g/mL}$) [18,19], apple ($IC_{50} = 1000 \mu\text{g/mL}$) [20], and Acacia bark ($IC_{50} =$
308 $38.0 \mu\text{g/mL}$) [21] display relatively weaker activity. It is difficult to clearly explain
309 the differences in inhibitory activity from the structures of procyanidins. However,
310 a high mDP and the presence of (gallo)catechin as the extension unit, which are
311 common to the strongly inhibiting procyanidins as well as the current AT-P, may
312 play an important role.

313 In conclusion, *A. thunbergii* potently prevented T2DM. AT decreased post-starch
314 administration blood glucose levels in a T2DM rat model. The procyanidin
315 contained in this material was isolated and characterized as the potent inhibitor
316 of α -amylase, which is responsible for the T2DM preventative effect of *A.*
317 *thunbergii*.

318

319 **Author contributions**

320 The study was designed by EK, YI, MK, and JK. The *in vivo* experiments were
321 constructed and performed under the responsibility of YI and MK. The *in vitro*
322 experiments were constructed and performed by EK and NK. The results were
323 discussed by all authors. The manuscript was written by EK, and all authors
324 commented on and revised the manuscript.

325

326 **Disclosure statement**

327 We have no potential conflict of interest to declare.

328

329 **Acknowledgements**

330 The authors thank Mr. Yusuke Takata and Dr. Eri Fukushi of the GC-MS and NMR
331 Laboratory, Faculty of Agriculture, Hokkaido University for their measurements of
332 mass spectra.

333

334 **References**

- 335 1. Krentz AJ, Bailey CJ. Oral antidiabetic agents: current role in type 2 diabetes
336 mellitus. *Drugs* 2005; **65**: 385–411.

337 2. Kokil GR, Veedu RN, Ramm G a., *et al.* Type 2 Diabetes Mellitus: Limitations
338 of Conventional Therapies and Intervention with Nucleic Acid-Based
339 Therapeutics. *Chem. Rev.* 2015; **115**: 4719–4743.

340 3. Nakagawa K. Studies Targeting α -Glucosidase Inhibition, Antiangiogenic
341 Effects, and Lipid Modification Regulation: Background, Evaluation, and
342 Challenges in the Development of Food Ingredients for Therapeutic
343 Purposes. *Biosci. Biotechnol. Biochem.* 2013; **77**: 900–908.

344 4. Komatsu K, Li X-B, Yamaji S, *et al.* Pharmacognostical Studies on the
345 Chinese Crude Drug ‘Shengma’ (I): General Structure of the Underground
346 Parts of Cimicifuga Plants, Morphological and Anatomical Variations of *C.*
347 *simplex* and ‘Shengma’ Derived from This Species. *Nat. Med.* 1996; **50**:
348 222–231.


349 5. Li X-B, Komatsu K, Yamaji S, *et al.* Pharmacognostical Studies on the
350 Chinese Crude Drug ‘Shengma’ (Part II): ‘Shengma’ Derived from Genus
351 Cimicifuga Plants. *Nat. Med.* 1997; **51**: 148–161.

352 6. Han L-K, Miura N, Kawano S, *et al.* Effects of *Astilbe thunbergii* Rhizomes

- 353 Extract on the Postprandial Blood Triacylglycerol Elevation. *Shoyakugaku*
354 *zasshi Japanese J. Pharmacogn.* 2006; **60**: 68–72.
- 355 7. Han L-K, Ninomiya H, Taniguchi M, *et al.* Norepinephrine-Augmenting
356 Lipolytic Effectors from *Astilbe t hunbergii* Rhizomes. *J. Nat. Prod.* 1998; **61**:
357 1006–1011.
- 358 8. Sun B, Ricardo-da-Silva JM, Spranger I. Critical Factors of Vanillin Assay for
359 Catechins and Proanthocyanidins. *J. Agric. Food Chem.* 1998; **46**:
360 4267–4274.
- 361 9. Hashimoto F, Nonaka G, Nishioka I. Tannins and related compounds. LXXVII.
362 Novel chalcan-flavan dimers, assamicains A, B and C, and a new flavan-3-ol
363 and proanthocyanidins from the fresh leaves of *Camellia sinensis* L. var.
364 *assamica* Kitamura. *Chem. Pharm. Bull.* 1989; **37**: 77–85.
- 365 10. Cai Y, Evans FJ, Roberts MF, *et al.* Polyphenolic compounds from *Croton*
366 *lechleri*. *Phytochemistry* 1991; **30**: 2033–2040.
- 367 11. Hansawasdi C, Kawabata J, Kasai T. α -Amylase Inhibitors from Roselle
368 (*Hibiscus sabdariffa* Linn.) Tea. *Biosci. Biotechnol. Biochem.* 2000; **64**:
369 1041–1043.
- 370 12. Al-awar A, Kupai K, Veszelka M, *et al.* Experimental Diabetes Mellitus in
371 Different Animal Models. *J. Diabetes Res.* 2016; **2016**: 1–12.

- 372 13. Robbins RJ, Leonczak J, Johnson JC, *et al.* Method performance and
373 multi-laboratory assessment of a normal phase high pressure liquid
374 chromatography-fluorescence detection method for the quantitation of
375 flavanols and procyanidins in cocoa and chocolate containing samples. *J.*
376 *Chromatogr. A* 2009; **1216**: 4831–4840.
- 377 14. Kelm MA, Johnson JC, Robbins RJ, *et al.* High-Performance Liquid
378 Chromatography Separation and Purification of Cacao (*Theobroma cacao*
379 L.) Procyanidins According to Degree of Polymerization Using a Diol
380 Stationary Phase. *J. Agric. Food Chem.* 2006; **54**: 1571–1576.
- 381 15. Han KH, Kitano-Okada T, Seo JM, *et al.* Characterisation of anthocyanins
382 and proanthocyanidins of adzuki bean extracts and their antioxidant
383 activity. *J. Funct. Foods* 2015; **14**: 692–701.
- 384 16. Wang H, Liu T, Song L, *et al.* Profiles and α -Amylase Inhibition Activity of
385 Proanthocyanidins in Unripe *Manilkara zapota* (Chiku). *J. Agric. Food Chem.*
386 2012; **60**: 3098–3104.
- 387 17. Wang H, Song L, Feng S, *et al.* Characterization of proanthocyanidins in
388 stems of *Polygonum multiflorum* thunb as strong starch hydrolase
389 inhibitors. *Molecules* 2013; **18**: 2255–2265.
- 390 18. Kawakami K, Aketa S, Nakanami M, *et al.* Major Water-Soluble Polyphenols,
391 Proanthocyanidins, in Leaves of Persimmon (*Diospyros kaki*) and Their
392 α -Amylase Inhibitory Activity. *Biosci. Biotechnol. Biochem.* 2010; **74**:

- 393 1380–1385.
- 394 19. Lee YA, Cho EJ, Tanaka T, *et al.* Inhibitory activities of proanthocyanidins
395 from persimmon against oxidative stress and digestive enzymes related to
396 diabetes. *J. Nutr. Sci. Vitaminol. (Tokyo)*. 2007; **53**: 287–292.
- 397 20. Yanagida A, Kanda T, Tanabe M, *et al.* Inhibitory effects of apple
398 polyphenols and related compounds on cariogenic factors of mutans
399 streptococci. *J. Agric. Food Chem.* 2000; **48**: 5666–5671.
- 400 21. Kusano R, Ogawa S, Matsuo Y, *et al.* α -Amylase and Lipase Inhibitory
401 Activity and Structural Characterization of Acacia Bark Proanthocyanidins. *J.*
402 *Nat. Prod.* 2011; **74**: 119–128.
- 403 22. Lin G-M, Lin H-Y, Hsu C-Y, *et al.* Structural characterization and bioactivity
404 of proanthocyanidins from indigenous cinnamon (*Cinnamomum*
405 *osmophloeum*). *J. Sci. Food Agric.* 2016; **96**: 4749–4759.
- 406 23. Tsujita T, Shintani T, Sato H. α -Amylase Inhibitory Activity from Nut Seed
407 Skin Polyphenols. 1. Purification and Characterization of Almond Seed Skin
408 Polyphenols. *J. Agric. Food Chem.* 2013; **61**: 4570–4576.
- 409



410
411 **Figure 1.** Result of sugar tolerance test with AT administration.

412 Male GK:Slc rats were orally given AT followed by sugar (A: starch, B: sucrose, C:
413 glucose). AT100: 100 mg/kg AT; AT300: 300 mg/kg AT; acarbose
414 (amylase/glucosidase inhibitor): 10 mg/kg; anagliptin (dipeptidyl peptidase 4
415 inhibitor): 10 mg/kg. Error bars indicate SD. * $p<0.05$, ** $p<0.01$ (Dunnett test).





Figure 2. Serum GLP-1 and insulin level after administration of AT.

Male GK:Slc rats were orally given AT and serum level of GLP-1 (A) and insulin was measured (B). AT100: 100 mg/kg AT; AT300: 300 mg/kg AT; anagliptin (dipeptidyl peptidase 4 inhibitor): 10 mg/kg. Error bars indicate SD. * $p<0.05$, ** $p<0.01$ (Dunnett test).




424

425 Figure 3. UV absorption and GPC analysis of AT-P.

426 (A) UV absorption of AT-P; (B) GPC analysis of AT-P with Shodex GF-510 HQ
 427 ($\phi 7.5 \times 300$ mm). X-mark indicates molecular size and retention time of the
 428 polystyrene standards.

429




430
431 Figure 4. HPLC chromatogram of thiolysis products.

432 Condition: column InertSustain C18 ($\phi 4.6 \times 250$ mm), mobile phase gradient
 433 elution from 20% aq. methanol containing 0.1% TFA to 95% aq. methanol
 434 containing 0.1% TFA with 60 min, flow rate 1.0 mL/min, detection 270 nm.
 435 Products: catechin (**1**), gallocatechin 4-benzylthioether (**2**), epigallocatechin
 436 4-benzylthioether (**3**), catechin 4-benzylthioether (**4**), (epi)gallocatechin gallate
 437 4-benzylthioether (**5**), epicatechin 4-benzylthioether (**6**), (epi)catechin gallate
 438 4-benzylthioether (**7**). The stereochemistry of **5** and **7** were not determined.

439
440 Table 1. Ratio of AT-P thiolysis products.

position	compound	% mol
terminal	catechin (1)	8.5±0.1
extention	gallocatechin 4-benzylthioether (2)	9.8±0.2
	epigallocatechin 4-benzylthioether (3)	31.6±0.8
	catechin 4-benzylthioether (4)	13.2±0.3
	(epi)gallocatechin gallate 4-benzylthioether (5)	1.6±0.0
	epicatechin 4-benzylthioether (6)	32.4±0.4
	(epi)catechin gallate 4-benzylthioether (7)	2.8±0.0
mDP		11.8±0.1



443

444 Figure 5. α -Amylase inhibitory activity of AT-P.

445 Acarbose (5 $\mu\text{g/mL}$) was used as positive control. Error bars indicate SEM.

446 ** $p<0.01$ (Dunnett test).

447